Skip to main content

14.06.2021 | Review

First international workshop of the ATM and cancer risk group (4-5 December 2019)

Familial Cancer
Fabienne Lesueur, Douglas F. Easton, Anne-Laure Renault, Sean V. Tavtigian, Jonine L. Bernstein, Zsofia Kote-Jarai, Rosalind A. Eeles, Dijana Plaseska-Karanfia, Lidia Feliubadaló, Banu Arun, Natalie Herold, Beatrix Versmold, Rita Katharina Schmutzler, Tú Nguyen-Dumont, Melissa C. Southey, Leila Dorling, Alison M. Dunning, Paola Ghiorzo, Bruna Samia Dalmasso, Eve Cavaciuti, Dorothée Le Gal, Nicholas J. Roberts, Mev Dominguez-Valentin, Matti Rookus, Alexander M. R. Taylor, Alisa M. Goldstein, David E. Goldgar, Dominique Stoppa-Lyonnet, Nadine Andrieu, Spanish ATM working group, GC-HBOC, CARRIERS and Ambry Groups
Wichtige Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1007/​s10689-021-00248-y.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


The first International Workshop of the ATM and Cancer Risk group focusing on the role of Ataxia-Telangiectasia Mutated (ATM) gene in cancer was held on December 4 and 5, 2019 at Institut Curie in Paris, France. It was motivated by the fact that germline ATM pathogenic variants have been found to be associated with different cancer types. However, due to the lack of precise age-, sex-, and site-specific risk estimates, no consensus on management guidelines for variant carriers exists, and the clinical utility of ATM variant testing is uncertain. The meeting brought together epidemiologists, geneticists, biologists and clinicians to review current knowledge and on-going challenges related to ATM and cancer risk. This report summarizes the meeting sessions content that covered the latest results in family-based and population-based studies, the importance of accurate variant classification, the effect of radiation exposures for ATM variant carriers, and the characteristics of ATM-deficient tumors. The report concludes that ATM variant carriers outside of the context of Ataxia-Telangiectasia may benefit from effective cancer risk management and therapeutic strategies and that efforts to set up large-scale studies in the international framework to achieve this goal are necessary.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Nur für berechtigte Nutzer zugänglich
Über diesen Artikel

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.